Author

Karen Snyder

Observed names: K SNYDER, K Snyder, Karen M. Snyder

Institution: Merck & Co., Inc., Rahway, NJ, USA (United States)

Observed institutions: Merck & Co., Inc., Rahway, NJ, USA (United States), SGS (Belgium)

OpenAlex ID: A5111519966

Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: Results from two randomized, double-blind, placebo-controlled studies with single oral doses

2005 · G HERMAN, C STEVENS, et al. · Clinical Pharmacology & Therapeutics · 517

Effect of Single Oral Doses of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on Incretin and Plasma Glucose Levels after an Oral Glucose Tolerance Test in Patients with Type 2 Diabetes

2006 · Gary A. Herman, Arthur Bergman, et al. · The Journal of Clinical Endocrinology & Metabolism · 497

Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: A double-blind, randomized, placebo-controlled study in healthy male volunteers

2006 · Arthur J. Bergman, Catherine Stevens, et al. · Clinical Therapeutics · 267

Pharmacokinetics and Pharmacodynamic Effects of the Oral DPP‐4 Inhibitor Sitagliptin in Middle‐Aged Obese Subjects

2006 · Gary A. Herman, Arthur Bergman, et al. · The Journal of Clinical Pharmacology · 188

Efficacy and Safety of Intranasal Peptide YY3–36 for Weight Reduction in Obese Adults

2007 · Ira Gantz, Ngozi Erondu, et al. · The Journal of Clinical Endocrinology & Metabolism · 164

Multiple-Dose Pharmacodynamics and Pharmacokinetics of Anacetrapib, a Potent Cholesteryl Ester Transfer Protein (CETP) Inhibitor, in Healthy Subjects

2008 · R Krishna, AJ Bergman, et al. · Clinical Pharmacology & Therapeutics · 100

Cerebrospinal Fluid Biomarkers Distinguish Postmortem-Confirmed Alzheimer's Disease from Other Dementias and Healthy Controls in the OPTIMA Cohort

2015 · Jeffrey L. Seeburger, Daniel J. Holder, et al. · Journal of Alzheimer s Disease · 97

High Resolution Discovery Proteomics Reveals Candidate Disease Progression Markers of Alzheimer’s Disease in Human Cerebrospinal Fluid

2015 · Ronald C. Hendrickson, Anita Y. H. Lee, et al. · PLoS ONE · 69

Single‐dose pharmacokinetics and pharmacodynamics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects

2009 · Rajesh Krishna, Amit Garg, et al. · British Journal of Clinical Pharmacology · 51

Comparative Inhibitory Activity of Etoricoxib, Celecoxib, and Diclofenac on COX‐2 Versus COX‐1 in Healthy Subjects

2008 · Jules I. Schwartz, Aimee L. Dallob, et al. · The Journal of Clinical Pharmacology · 49

Evaluation of pharmacokinetic parameters and dipeptidyl peptidase‐4 inhibition following single doses of sitagliptin in healthy, young Japanese males

2010 · Gary A. Herman, Goutam C. Mistry, et al. · British Journal of Clinical Pharmacology · 40

P3‐092: Prediction of short‐term and long‐term cognitive decline in moderate Alzheimer's disease patients in the Oxford project to investigate memory and aging (optima) cohort using CSF biomarkers

2008 · Jeffrey L. Seeburger, Daniel Holder, et al. · Alzheimer s & Dementia · 1

P2–165: A multi–analyte panel of six CSF biomarkers classifies AD and control in pathologically confirmed Alzheimer subjects within the OPTIMA cohort

2006 · Adam J. Simon, Viswanath Devanarayan, et al. · Alzheimer s & Dementia

Works count: 13

Citation count: 2,040

H-index: 11

I10-index: 11